Stacey Darrisaw, RN, CCM | |
2020 7th Ave, Columbus, GA 31904-8914 | |
(762) 822-1242 | |
(706) 494-4445 |
Full Name | Stacey Darrisaw |
---|---|
Gender | Female |
Speciality | Case Management |
Location | 2020 7th Ave, Columbus, Georgia |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1104448281 | NPI | - | NPPES |
Mailing Address | Practice Location Address |
---|---|
Stacey Darrisaw, RN, CCM 49 Westwood Way, Fortson, GA 31808-6069 Ph: (762) 822-1242 | Stacey Darrisaw, RN, CCM 2020 7th Ave, Columbus, GA 31904-8914 Ph: (762) 822-1242 |
News Archive
Duke biomedical engineers have received more than $2.2 million from the National Institutes of Health (NIH) to continue their explorations of how the complex moving and flexing of blood vessels during a heartbeat might contribute to heart disease.
Glaucoma is one of the leading causes of blindness worldwide. A major risk factor for glaucoma is elevated eye pressure due to poor drainage of aqueous humor, the fluid that provides nutrients to the eye.
Atherotech Diagnostics Lab will showcase its VAP Cholesterol Test in booth 324 at the American Osteopathic Association's 115th Annual Osteopathic Medical Conference & Exposition (OMED 2010). The gathering of DOs, residents, interns, students, researchers and health care professionals will be held October 24-28 at Moscone Convention Center in San Francisco.
Moerae Matrix Inc. announced today the initiation of its second Phase 1 clinical trial with MMI-0100, a first-in-class inhibitor of MAPKAP kinase 2 (MK2) that is being developed for pulmonary disorders characterized by inflammation and fibrosis. The study, conducted in the United Kingdom, is a double-blind, two-way cross-over design lipopolysaccharide (LPS) challenge study further evaluating the safety and tolerability of MMI-0100 when given via inhalation to healthy subjects who smoke.
› Verified 2 days ago